The term triple-negative breast cancer (TNBC) is defined by negative clinical testing for three receptors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) amplification [65]. This evidence concerns the gene PGR and triple-negative breast carcinoma.